Bokf Na Acquires 152 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Bokf Na increased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 4.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,946 shares of the medical instruments supplier’s stock after buying an additional 152 shares during the period. Bokf Na’s holdings in West Pharmaceutical Services were worth $1,562,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Epoch Investment Partners Inc. grew its position in shares of West Pharmaceutical Services by 16.6% in the first quarter. Epoch Investment Partners Inc. now owns 260,519 shares of the medical instruments supplier’s stock valued at $103,090,000 after purchasing an additional 37,051 shares in the last quarter. LRI Investments LLC bought a new stake in shares of West Pharmaceutical Services during the first quarter valued at about $86,000. Toronto Dominion Bank lifted its holdings in shares of West Pharmaceutical Services by 2.1% in the first quarter. Toronto Dominion Bank now owns 42,275 shares of the medical instruments supplier’s stock worth $16,729,000 after buying an additional 862 shares in the last quarter. Advisors Asset Management Inc. boosted its position in shares of West Pharmaceutical Services by 12.9% in the first quarter. Advisors Asset Management Inc. now owns 5,639 shares of the medical instruments supplier’s stock valued at $2,231,000 after acquiring an additional 645 shares during the period. Finally, Vident Advisory LLC increased its holdings in West Pharmaceutical Services by 467.5% during the 1st quarter. Vident Advisory LLC now owns 9,511 shares of the medical instruments supplier’s stock worth $3,764,000 after acquiring an additional 7,835 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

NYSE:WST traded up $7.60 during trading hours on Friday, hitting $284.76. The stock had a trading volume of 1,190,418 shares, compared to its average volume of 675,234. The firm has a market capitalization of $20.74 billion, a price-to-earnings ratio of 37.57, a P/E/G ratio of 6.03 and a beta of 1.00. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $415.73. The company has a 50 day simple moving average of $324.09 and a two-hundred day simple moving average of $355.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 18.78%. West Pharmaceutical Services’s quarterly revenue was down 6.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.11 EPS. Research analysts forecast that West Pharmaceutical Services, Inc. will post 6.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the sale, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares of the company’s stock, valued at $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.